Chinese domestic antibody drug industry in 2017 counts 200 companies with 22 approved species and about 200 drug applications

Sina Publisher has published a detailed map on Chinese antibody producers. The authors come to the conclusion that a) the number of producers is consolidating, b) autoimmune diseases and cancer application accounts for 78% market share of antibody drugs, c) for the next 10 years, domestic producers will focus on the development of generic or me-better antibodies

China Bio news release, August 28, 2017

Chinese domestic antibody drug industry in 2017 counts 200 companies with 22 approved species and about 200 drug applications
Scroll to top